Aninye, Irene O. http://orcid.org/0000-0002-1747-9148
Digre, Kathleen
Hartnett, M. Elizabeth
Baldonado, Kira
Shriver, Erin M.
Periman, Laura M.
Grutzmacher, Julie
Clayton, Janine A.
,
Funding for this research was provided by:
Horizon Pharmaceuticals
Article History
Received: 9 April 2021
Accepted: 8 October 2021
First Online: 20 October 2021
Declarations
:
: Not applicable.
: Not applicable.
: Individual members of the SWHR Women’s Eye Health Working Group have not been provided any compensation for their participation in the SWHR Working Group or for the development of this manuscript. JAC is an employee of the United States Government. KD receives royalties from Springer for a book on eye pain. MEH receives funding from the National Institutes of Health/National Eye Institute (R01 EY017011, EY015130). KD and MEH are also supported in part by an Unrestricted Grant from Research to Prevent Blindness, Inc., New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah. LMP consults for Alcon, Allegran, Bruder, Dompe, Eyedetec Medical Inc., Eyevance Pharmaceuticals, Horizon Therapeutics, Kala Pharmaceuticals, Johnson & Johnson, Olympic Opthalmics Inc., Omera, Novartis, NuSight Medical, ScienceBased Health, Sun Pharmaceutical Industries Ltd, TearLab Corporation, and Therma-Med Inc., and has equity in QuenchDry Eye and Wellness26™. EMS consults for Horizon Therapeutics. All other authors have no competing interests to report.